Navigation Links
DelMar Pharmaceuticals to Present Interim Clinical Data for VAL-083 in Glioblastoma at Society of Neuro-Oncology
Date:11/14/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 14, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") today announced that the Company will present interim clinical trial data for VAL-083 in glioblastoma at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) being held in conjunction with the 18th Annual Society for Neuro-Oncology (SNO) meeting. The WFNO/SNO meeting will take place November 21st through 24th in San Francisco.  Glioblastoma is the most common and aggressive form of brain cancer, and new therapies are greatly needed.

DelMar will present the poster entitled, "Phase I/II study of VAL-083 in patients with recurrent malignant glioma or progressive-secondary brain tumor," from 7 pm to 9 pm on Friday, November 22nd. The abstract, number MR-028, is now published in the Journal of Neuro-Oncology and can also be found by clicking here.

About VAL-083
VAL-083 represents a first-in-class, small-molecule chemotherapeutic with a unique mechanism of action. In more than 40 Phase 1 and 2 clinical studies sponsored by the National Cancer Institute (NCI), VAL-083 has shown safety and efficacy in treating a number of cancers including lung, brain, cervical, ovarian tumors and leukemia. VAL-083 is approved in China for the treatment of chronic myelogenous leukemia and lung cancer and has received orphan drug designation in Europe and the U.S. for the treatment of gliomas.  As a potential treatment for glioblastoma, VAL-083's mechanism of action is unaffected by the expression of MGMT
'/>"/>

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
2. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
3. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
4. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
5. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
6. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
7. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
8. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
9. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
10. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
11. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
(Date:1/15/2014)... 15, 2014  In an unprecedented effort to curb the spread of ... other transport vehicles, an advanced and portable UV germicidal lamp manufactured ... first time. In order to prevent EMS paramedics ... West Palm Beach Fire Rescue is the ...
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... April 28, 2011 The U.S. Food and ... combination with prednisone (a steroid) to treat patients ... received prior docetaxel (chemotherapy). (Logo: ... male sex hormone testosterone stimulates prostate tumors to ...
... -- When running a company, school or hotel, we ... which presents us with everything completely and obviously. It ... need exact test data to diagnose properly. Shenzhen Wuzhou ... of equipment for sale including digital and infrared ...
Cached Medicine Technology:FDA Approves Zytiga for Late-Stage Prostate Cancer 2FDA Approves Zytiga for Late-Stage Prostate Cancer 3Testing With Data to Get a More Convenient Diagnosis 2
(Date:7/10/2014)... Estonian-born Katerina Alba,s research at the University of Huddersfield ... the most popular emulsion-based food products such as ... is starting to gain an international profile for her ... and food science at the University and now she ... with her supervisor, Dr Vassilis Kontogiorgos, she is investigating ...
(Date:7/10/2014)... A neuroscientist at Rutgers University-Newark says the human brain ... a finding that could provide a better understanding ... conditions that afflict an estimated 13.6 million Americans. , ... , Michael Cole, an assistant professor at the Center ... brain architecture of a person at rest is basically ...
(Date:7/10/2014)... sarcomas research group at the Bellvitge Biomedical Research Institute ... been tested in 19 patients a new therapeutic combination ... indicate that the new treatment could stabilize the growth ... the British Journal of Cancer ., Sarcomas ... complex since there are several subtypes. It can affect ...
(Date:7/10/2014)... 10, 2014) Men who experience hot flashes are ... find relief from their silent suffering if they ... findings from a Baylor University case study., After seven ... had uncontrolled hot flashes following prostate cancer surgery showed ... also an impressive improvement in sleep quality, according to ...
(Date:7/9/2014)... that sudden, acute episodes of low back pain are ... air pressure, wind direction and precipitation. Findings published in ... the American College of Rheumatology (ACR), indicate that the ... wind speed or wind gusts, but was not clinically ... (WHO) nearly everyone experiences low back pain at some ...
Breaking Medicine News(10 mins):Health News:World interest in research work on the benefits of the Okra plant 2Health News:Working to loosen the grip of severe mental illness 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Low back pain? Don't blame the weather 2
... might spur obesity, German study finds , FRIDAY, Aug. 7 ... financial debt, German researchers suggest. , In their study, Eva ... the weight of more than 9,000 people. , They found ... debt were classified as obese, a full quarter of those ...
... , , CENTENNIAL, Colo., Aug. 7 ... and soft tissue allografts for use in surgical procedures, announced today that ... in the Healthcare category of the Top Company awards program hosted by ... is hosting the business awards program for the 22nd consecutive year. ...
... , , , ... WCRX ) today announced its results for the quarter ... 2009 increased 7.1% to $250.8 million over the prior year quarter. ... sales of DORYX, LOESTRIN 24 FE and ESTRACE Cream which were ...
... ... onsite employee health services and technology solutions, today announced the opening of a Chicago field ... region. , ... August 7, 2009 -- Marathon Health, a leading provider of onsite employee health services ...
... and most expensive patients need fewer health care resources and ... nurse-physician primary care team that tracks their health and offers ... Johns Hopkins Bloomberg School of Public Health. The research, published ... that in the first eight months of a randomized controlled ...
... rate of heart attack, tripled rate of death seen ... New research shows that men diagnosed with the chest ... neither artery-opening angioplasty nor coronary-bypass surgery reduced long-term mortality ... newly diagnosed with angina at 40 primary-care practices in ...
Cached Medicine News:Health News:Slide Into Debt Could Bring Wider Waistline 2Health News:AlloSource Chosen as Healthcare Finalist in 2009 'Top Companies' 2Health News:AlloSource Chosen as Healthcare Finalist in 2009 'Top Companies' 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 4Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 6Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 7Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 8Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 9Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 10Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 11Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 12Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 13Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 14Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 15Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 16Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 17Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 18Health News:Marathon Health Expands Midwest Presence 2Health News:Guided care reduces cost of health care for older persons with chronic conditions 2Health News:Men With Angina Do Worse Than Women 2Health News:Men With Angina Do Worse Than Women 3
1% tryptone, 0.5% yeast extract, 1.0% Sodium Chloride. 1.5% agararose...
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
... flowing powder. pH: pH(4.7%, H 2 O): ... Yeast Extract: 47% Potassium Phosphate Dibasic: 25% Potassium ... 47 gm powder per liter of purified water. ... and recombinant proteins than LB media by allowing ...
1.2% Tryptone, 2.4% Yeast Extract, 0.4% Glycerol, with 100ml of 10x Phosphate buffer supplement (0190-01)....
Medicine Products: